H.E. Youssef Mekkawy toured the facility where plasma-derived medicines for Grifols Egypt are manufactured from Egyptian plasma until a new production site in Egypt is operational. World-class engineering is currently being applied to the manufacturing site at the New Administrative Captial's Medical City.

In addition, H.E. singled out the advanced automation of the operations and strict adherence to the highest international levels of quality and safety, characteristics that will also define the new GEPD manufacturing facilities. Once completed at the end of 2025 and operational, the site will produce the Grifols Egypt plasma-derived products that Parets del Vallès is manufacturing in the meantime.

The Ambassador reaffirmed Egypt’s commitment to Grifols Egypt for Plasma Derivatives, a joint venture between Grifols and NSPO to develop a fully integrated plasma-supply infrastructure that ensures domestic and regional self-sufficiency in plasma-derived medicines.

During his institutional visit, his first to Grifols, he met with company executives including Thomas Glanzmann, Executive Chairman and CEO; Raimon Grifols, Chief Corporate Officer; Victor Grifols Deu, Chief Operating Officer, as well as Grifols board member Tomás Dagà. Present from Grifols Egypt were Dr. Magdy Amin, CEO; and Dr. Ahmed Serag, Head of Strategy and Projects.

-----------

Last week Grifols Egypt announced it is about to deliver its first shipment of medicines – albumin – to local hospitals.

All plasma for Grifols Egypt treatments comes from Egyptian donors and a growing network of plasma centers in the country. Six are open, another four are expected to be running before year-end, and in 2024 a total of 20 centers will be accepting donations.

Grifols and the Egyptian government’s (NSPO) are making great strides in their joint venture to ensure Egypt’s self-sufficiency in plasma medicines.